UY37421A - Método para producir la forma cristalina de modificación a de calcobutrol - Google Patents
Método para producir la forma cristalina de modificación a de calcobutrolInfo
- Publication number
- UY37421A UY37421A UY0001037421A UY37421A UY37421A UY 37421 A UY37421 A UY 37421A UY 0001037421 A UY0001037421 A UY 0001037421A UY 37421 A UY37421 A UY 37421A UY 37421 A UY37421 A UY 37421A
- Authority
- UY
- Uruguay
- Prior art keywords
- modification
- calcolutrol
- producing
- crystal form
- high purity
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000012986 modification Methods 0.000 title abstract 3
- 230000004048 modification Effects 0.000 title abstract 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- ZPDFIIGFYAHNSK-CTHHTMFSSA-K 2-[4,10-bis(carboxylatomethyl)-7-[(2r,3s)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) Chemical compound [Gd+3].OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-CTHHTMFSSA-K 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052688 Gadolinium Inorganic materials 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- ZPDFIIGFYAHNSK-UHFFFAOYSA-K gadobutrol Chemical compound [Gd+3].OCC(O)C(CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-UHFFFAOYSA-K 0.000 abstract 1
- 229960003411 gadobutrol Drugs 0.000 abstract 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000006408 oxalic acid Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describe un método para la producción de un compuesto con pureza elevada de la fórmula (I) en forma cristalina de la modificación A. En esto, comenzando a partir de gadobutrol de elevada pureza, se elimina el gadolinio por descomplejación con ácido oxálico, y luego con una sal cálcica se produce el complejo cálcico con pureza elevada. Durante la cristalización, se establece un equivalente de agua del 9 - 11 % en peso. Se emplea la forma cristalina de la modificación A del compuesto de la fórmula (I) en la producción de Gadovist.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16190812 | 2016-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37421A true UY37421A (es) | 2018-01-31 |
Family
ID=57003447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037421A UY37421A (es) | 2016-09-27 | 2017-09-27 | Método para producir la forma cristalina de modificación a de calcobutrol |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10793532B2 (es) |
| EP (1) | EP3519394B1 (es) |
| JP (2) | JP7053590B2 (es) |
| KR (1) | KR102395523B1 (es) |
| CN (1) | CN109803958B (es) |
| AR (1) | AR109729A1 (es) |
| AU (1) | AU2017333698B2 (es) |
| BR (1) | BR112019006066A2 (es) |
| CA (1) | CA3038036C (es) |
| CY (1) | CY1123317T1 (es) |
| DK (1) | DK3519394T3 (es) |
| ES (1) | ES2809736T3 (es) |
| HR (1) | HRP20200922T1 (es) |
| HU (1) | HUE050553T2 (es) |
| IL (1) | IL265536B (es) |
| LT (1) | LT3519394T (es) |
| MX (1) | MX2019003540A (es) |
| NZ (1) | NZ751256A (es) |
| PL (1) | PL3519394T3 (es) |
| PT (1) | PT3519394T (es) |
| RS (1) | RS60392B1 (es) |
| SG (1) | SG11201901460UA (es) |
| SI (1) | SI3519394T1 (es) |
| TW (1) | TWI765913B (es) |
| UY (1) | UY37421A (es) |
| WO (1) | WO2018059914A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2809736T3 (es) * | 2016-09-27 | 2021-03-05 | Bayer Pharma AG | Método para producir la forma cristalina de modificación a de calcobutrol |
| US20210380542A1 (en) * | 2018-10-24 | 2021-12-09 | Biophore India Pharmaceuticals Pvt. Ltd | Novel process for the preparation of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetra azacyclododecane-1,4,7-triyl) triacetic acid and it's complexes with paramagnetic metal ions |
| CN111039885B (zh) * | 2019-12-06 | 2021-03-05 | 广州康瑞泰药业有限公司 | 一种制备高纯度考布曲钙的方法 |
| KR20210112910A (ko) * | 2020-03-06 | 2021-09-15 | 주식회사 엔지켐생명과학 | 가도부트롤 주사제 제조를 위한 부형제인 칼코부트롤의 제조 방법 |
| KR20210114742A (ko) * | 2020-03-11 | 2021-09-24 | 주식회사 엔지켐생명과학 | 칼테리돌의 제조방법 |
| CN114573522A (zh) * | 2020-11-30 | 2022-06-03 | 江苏恒瑞医药股份有限公司 | 一种考布曲钙的新晶型及其制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1491129A (en) | 1975-06-04 | 1977-11-09 | Guerbet Sa | Iodo-benzene derivatives and an x-ray contrast medium containing them |
| US4284620A (en) | 1979-03-23 | 1981-08-18 | Mallinckrodt, Inc. | N-(2-Hydroxyethyl)-2,4,6-triiodo-3,5-bis-(2-keto-L-gulonamido)benzamide and radiological compositions containing same |
| NO161560C (no) | 1980-04-17 | 1989-09-06 | Univ California | Symmetriske trijodisoftaldiamid-derivater og roentgenkontrastmidler inneholdende disse. |
| DE3150916A1 (de) | 1981-12-18 | 1983-06-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | N-hydroxyaethylierte 2,4,6-trijodaminoisiophthalsaeure-bis- trihydroxybutylamide, deren herstellung und diese enthaltende roentgenkontrastmittel" |
| US5064633A (en) | 1984-06-04 | 1991-11-12 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes, their formulations and use |
| US5059412A (en) | 1984-06-04 | 1991-10-22 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| MX174467B (es) | 1986-01-23 | 1994-05-17 | Squibb & Sons Inc | 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos |
| DE3625417C2 (de) | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecan-Derivate |
| DE3640708C2 (de) | 1986-11-28 | 1995-05-18 | Schering Ag | Verbesserte metallhaltige Pharmazeutika |
| DE4009119A1 (de) | 1990-03-19 | 1991-09-26 | Schering Ag | 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| PT97124A (pt) | 1990-03-23 | 1991-12-31 | Gist Brocades Nv | Processo para a prparacao de composicoes inibidoras de interleucina - 6 (il-6) |
| DE4035760A1 (de) | 1990-11-08 | 1992-05-14 | Schering Ag | Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| DE4237943C2 (de) | 1992-11-06 | 1997-10-23 | Schering Ag | Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate |
| US5410043A (en) | 1991-12-06 | 1995-04-25 | Schering Aktiengesellschaft | Process for the production of mono-N-substituted tetraaza macrocycles |
| DE4218744C2 (de) | 1992-06-04 | 1997-11-06 | Schering Ag | Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe |
| DE4318369C1 (de) | 1993-05-28 | 1995-02-09 | Schering Ag | Verwendung von makrocyclischen Metallkomplexen als Temperatursonden |
| US5358704A (en) | 1993-09-30 | 1994-10-25 | Bristol-Myers Squibb | Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents |
| IT1275426B (it) | 1995-05-16 | 1997-08-07 | Bracco Spa | Recupero del gadolinio e dei suoi agenti complessanti da soluzioni acquose contenenti i loro complessi |
| DE19724186C2 (de) | 1997-06-02 | 2002-07-18 | Schering Ag | Verfahren zur Mono- und 1,7-Bis-N-ß-Hydroxyalkylierung von Cyclen und die entsprechenden N-ß-Hydroxyalkyl-1,4,7,10-tetraazacyclododecan-Li-Salz-Komplexe |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| DE102009053171B4 (de) | 2009-11-04 | 2011-07-21 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol) |
| RS60001B1 (sr) * | 2011-04-21 | 2020-04-30 | Bayer Ip Gmbh | Pripremanje gadobutrola visoke čistoće |
| JP2014516080A (ja) * | 2011-06-08 | 2014-07-07 | エスティーアイ ファーマ， エルエルシー | 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤 |
| KR101693400B1 (ko) * | 2014-09-17 | 2017-01-05 | 에스티팜 주식회사 | 칼코부트롤의 제조방법 |
| CN105037288B (zh) * | 2015-07-23 | 2017-11-03 | 上海现代制药海门有限公司 | 一种布醇的制备方法 |
| CN106187930B (zh) * | 2016-07-12 | 2018-10-19 | 嘉实（湖南）医药科技有限公司 | 高纯度考布曲钙的制备方法 |
| ES2809736T3 (es) | 2016-09-27 | 2021-03-05 | Bayer Pharma AG | Método para producir la forma cristalina de modificación a de calcobutrol |
-
2017
- 2017-09-11 ES ES17768733T patent/ES2809736T3/es active Active
- 2017-09-11 AU AU2017333698A patent/AU2017333698B2/en active Active
- 2017-09-11 SG SG11201901460UA patent/SG11201901460UA/en unknown
- 2017-09-11 MX MX2019003540A patent/MX2019003540A/es unknown
- 2017-09-11 KR KR1020197008763A patent/KR102395523B1/ko active IP Right Grant
- 2017-09-11 LT LTEP17768733.2T patent/LT3519394T/lt unknown
- 2017-09-11 IL IL265536A patent/IL265536B/en unknown
- 2017-09-11 PL PL17768733T patent/PL3519394T3/pl unknown
- 2017-09-11 DK DK17768733.2T patent/DK3519394T3/da active
- 2017-09-11 JP JP2019516489A patent/JP7053590B2/ja active Active
- 2017-09-11 NZ NZ751256A patent/NZ751256A/en unknown
- 2017-09-11 SI SI201730298T patent/SI3519394T1/sl unknown
- 2017-09-11 BR BR112019006066A patent/BR112019006066A2/pt not_active Application Discontinuation
- 2017-09-11 WO PCT/EP2017/072683 patent/WO2018059914A1/en active Application Filing
- 2017-09-11 HU HUE17768733A patent/HUE050553T2/hu unknown
- 2017-09-11 US US16/336,217 patent/US10793532B2/en active Active
- 2017-09-11 RS RS20200654A patent/RS60392B1/sr unknown
- 2017-09-11 CN CN201780058632.5A patent/CN109803958B/zh active Active
- 2017-09-11 EP EP17768733.2A patent/EP3519394B1/en active Active
- 2017-09-11 CA CA3038036A patent/CA3038036C/en active Active
- 2017-09-11 PT PT177687332T patent/PT3519394T/pt unknown
- 2017-09-27 UY UY0001037421A patent/UY37421A/es unknown
- 2017-09-27 TW TW106133043A patent/TWI765913B/zh active
- 2017-09-27 AR ARP170102671A patent/AR109729A1/es unknown
-
2020
- 2020-06-09 HR HRP20200922TT patent/HRP20200922T1/hr unknown
- 2020-07-30 CY CY20201100709T patent/CY1123317T1/el unknown
- 2020-09-22 US US17/028,467 patent/US11390592B2/en active Active
-
2022
- 2022-03-03 JP JP2022032582A patent/JP7444914B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37421A (es) | Método para producir la forma cristalina de modificación a de calcobutrol | |
| CL2017001978A1 (es) | Producción de compuestos de litio de alta pureza directamente a partir de salmueras que contienen litio | |
| PH12016502334A1 (en) | Method for producing fused heterocyclic compound | |
| AR066130A1 (es) | Formas cristalinas de saxagliptina y procesos para preparar las mismas | |
| EA201200652A1 (ru) | Способ получения кальцобутрола | |
| CR20150663A (es) | Derivados de diazacarbazol como ligandos de tau para pet | |
| CO6541539A2 (es) | Procesos para preparar las formas cristalinas a y b de ilaprazol y proceso para convertir las formas cristalinas | |
| WO2014128545A3 (en) | An improved process for the preparation of dolutegravir | |
| AR095297A1 (es) | Método para preparar un compuesto de piripiropeno | |
| MY178407A (en) | Process for the production of solid cooling agents | |
| AR102915A1 (es) | Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable | |
| NZ601805A (en) | Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same | |
| ECSP099708A (es) | Nuevos métodos | |
| EA201991921A1 (ru) | Способы получения ag-10, его промежуточных соединений и их солей | |
| NZ718607A (en) | Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines | |
| DOP2011000007A (es) | Produccion de concetrados de sulfato de cinc de una solucion diluida de sulfato de cinc. | |
| CL2017001377A1 (es) | Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos | |
| CL2012000270A1 (es) | Procedimiento de preparacion de ivabradina y de sus sales de adicion por formacion del anillo benzoacepino; y los compuestos intermediarios considerados en el procedimiento. | |
| MX2017014319A (es) | Sal sodica de inhibidor de transportador de acido urico y su forma cristalina. | |
| NZ606180A (en) | (20r,25s)-2-methylene-19,26-dinor-1α, 25-dihydroxyvitamin d3 in crystalline form | |
| EA201791329A1 (ru) | Новые кристаллические формы мононатриевой соли форамсульфурона | |
| AR101487A1 (es) | Formas cristalinas de un modulador de receptor de estrógeno | |
| UA111329C2 (uk) | Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою | |
| AR094240A1 (es) | Proceso para producir cristal de compuesto de pirazol | |
| CL2012001528A1 (es) | Proceso para preparar la forma cristalina a de ilaprazol a partir de una sal inorganica de ilaprazol y posterior neutralizacion de la sal con un acido en un solvente de reaccion; y proceso para preparar la forma cristalina b de ilaprazol en la forma cristalina a de ilaprazol. |